机构:[1]Department of Breast Cancer, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.河北医科大学第四医院外一科临床科室[2]Department of Tumor Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.河北医科大学第四医院[3]Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.河北医科大学第四医院
第一作者机构:[1]Department of Breast Cancer, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
通讯作者:
通讯机构:[1]Department of Breast Cancer, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.[*1]Department of Breast Cancer Center, The Fourth Hospital of Hebei Medical University, 169 Tianshan Street, Shijiazhuang 050000, Hebei, China
推荐引用方式(GB/T 7714):
Yang Chao,Liu Liang,Gao Chao,et al.Circ_0,007,331 Promotes the PTX Resistance and Progression of Breast Cancer via miR-200b-3p/ANLN[J].JOURNAL OF SURGICAL RESEARCH.2022,279:619-632.doi:10.1016/j.jss.2022.05.004.
APA:
Yang Chao,Liu Liang,Gao Chao,Zhang Geng,Zhang Yanshou...&Liu Yunjiang.(2022).Circ_0,007,331 Promotes the PTX Resistance and Progression of Breast Cancer via miR-200b-3p/ANLN.JOURNAL OF SURGICAL RESEARCH,279,
MLA:
Yang Chao,et al."Circ_0,007,331 Promotes the PTX Resistance and Progression of Breast Cancer via miR-200b-3p/ANLN".JOURNAL OF SURGICAL RESEARCH 279.(2022):619-632